We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market then they hit a snag – payers didn’t like the look of the price tag.